rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects

SIMPLE SUMMARY: In our prior study, we demonstrated that recombinant human epidermal growth factor (rhEGF) treatment is effective for managing epidermal growth factor receptor inhibitors (EGFRIs)-related skin toxicities and improves patients’ quality of life (QoL) compared with placebo. Nevertheless...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Kim, Ji Min, Ji, Jun Ho, Kim, Young Saing, Lee, Suee, Oh, Sung Yong, Huh, Seok Jae, Son, Choon Hee, Kang, Jung Hun, Ahn, So Yun, Choo, Jung Eun, Song, Ki-Hoon, Roh, Mee Sook
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692663/
https://ncbi.nlm.nih.gov/pubmed/33113881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113120
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak